Citation Impact
Citing Papers
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
2005 Standout
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
2006
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
2016 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Recombinant and Natural Human Interferons: Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies
2011
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications
2015 Standout
Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg/L: A Matched Cohort Study
2013
Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections
2014
Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
2010 Standout
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
2010 Standout
Sjögren's syndrome
2005 Standout
Cystic fibrosis
2016 Standout
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Contemporary epidemiology and prognosis of septic shock in infective endocarditis
2012
Androgen Deprivation Therapy, Insulin Resistance, and Cardiovascular Mortality: An Inconvenient Truth
2008
Pancreatic enzyme replacement therapy for people with cystic fibrosis
2014
A review of stimuli-responsive nanocarriers for drug and gene delivery
2008 Standout
Cognitive impairment in multiple sclerosis
2008 Standout
Immune-mediated side-effects of cytokines in humans
1995
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
Spondylodiscitis: update on diagnosis and management
2010
Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis
2013
Preclinical safety testing of biotechnology-derived pharmaceuticals
2004
Multiple sclerosis
2008 Standout
Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis
2002
Daptomycin Versus Vancomycin for Bloodstream Infections Due to Methicillin-Resistant Staphylococcus aureus With a High Vancomycin Minimum Inhibitory Concentration: A Case-Control Study
2011
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
2003
Induction of neutralising antibodies restricts the use of human granulocyte/macrophage colony stimulating factor for vaccine studies in rhesus macaques
2004 StandoutNobel
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
2002
Meta-analysis of Randomized Controlled Trials of Vancomycin for the Treatment of Patients With Gram-Positive Infections: Focus on the Study Design
2012
The efficacy of surgical treatment of cancer – 20years later
2014
Outpatient parenteral antibiotic therapy for infective endocarditis: a review of 4 years' experience at a UK centre
2012
Predicting Risk for Death from MRSA Bacteremia1
2012
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
2006 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Vertebral Osteomyelitis
2010 Standout
Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed
2004
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
2019
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Cisplatin: The first metal based anticancer drug
2019 Standout
Multiple Sclerosis
2000 Standout
Drug targeting using thermally responsive polymers and local hyperthermia
2001
Potential commercial applications of microbial surfactants
2000 Standout
Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials
2015 Standout
Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34+ hematopoietic progenitor cells
2000
An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis
2011 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins
2005
TAN-1511 A, B and C, Microbial Lipopeptides with G-CSF and GM-CSF Inducing Activity.
1995
Safety and Efficacy of Daptomycin in the Treatment of Osteomyelitis: Results from the CORE®Registry
2009
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
2014 Standout
Rapid responses to anakinra in patients with refractory adult‐onset Still's disease
2005
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Interferons in relapsing remitting multiple sclerosis: a systematic review
2003
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
2004 Standout
Multiple sclerosis
2002 Standout
Stimuli-responsive polymers and their applications in drug delivery
2009
High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.
1994
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Recent progress in the diagnosis and treatment of multiple sclerosis
1999
A comparison of different antibiotic regimens for the treatment of infective endocarditis
2016
Revised diagnostic criteria for neuromyelitis optica
2006 Standout
Human mesenchymal stem cells modulate allogeneic immune cell responses
2004 Standout
Interventions for preventing oral mucositis for patients with cancer receiving treatment
2011
A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS
2002
Stimuli-reponsive polymers and their bioconjugates
2004 Standout
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
2011 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Immunological and Inflammatory Functions of the Interleukin-1 Family
2009 Standout
2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adultsa
2015 Standout
Interferon in the Treatment of Cutaneous T-cell Lymphoma
1995
Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of Americaa
2012 Standout
Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.
1999
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
2020 Standout
The Inflammasomes: Guardians of the Body
2009 Standout
Interventions for treating oral mucositis for patients with cancer receiving treatment
2010
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infectionsa
2012 Standout
Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis
2000
Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis
2007 Standout
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
2015 ESC Guidelines for the management of infective endocarditis
2015 Standout
Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer
2010
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]
2002
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of M. Campion being referenced
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
1998
Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy
2009
Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis
2009
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates
2008
Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia
2007
Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation
1993
Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study
1994
Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study
1994
The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix
2004
Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer.
1995
Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.
1989
The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix
2004
Reproducibility of coefficient of fat absorption (CFA) in cystic fibrosis patients with pancreatic insufficiency
2010
Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
1995